Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 84-91, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (12)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kollroser, M.
Right arrow Articles by Schober, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kollroser, M.
Right arrow Articles by Schober, C.
Related Collections
Right arrow Hemostasis and Thrombosis
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 2002;48:84-91.)
© 2002 American Association for Clinical Chemistry, Inc.

Determination of Coumarin-type Anticoagulants in Human Plasma by HPLC-Electrospray Ionization Tandem Mass Spectrometry with an Ion Trap Detector

Manfred Kollroser1a and Caroline Schober2

1 Institute of Forensic Medicine, Karl-Franzens University Graz, Universitätsplatz 4, A8010 Graz, Austria.

2 Institute of Molecular Biology, Biochemistry, and Microbiology, Karl-Franzens University Graz, Heinrichstrasse 31a, A8010 Graz, Austria.

aAuthor for correspondence. Fax 43-316-380-9655; e-mail manfred.kollroser{at}kfunigraz.ac.at.

Background: Coumarin-type anticoagulants are used for the long-term treatment and prevention of thromboembolic disorders. The identification of these drugs is crucial in patients with an increased prothrombin time of unknown origin. The aim of this study was to develop a sensitive and specific method for the simultaneous determination of phenprocoumon, acenocoumarol, and warfarin in human plasma by HPLC-electrospray ionization tandem mass spectrometry.

Methods: After addition of the internal standard, p-chlorowarfarin, plasma samples were extracted using Oasis® MCX solid-phase extraction cartridges. The compounds were separated on a Symmetry C18 column (Waters) with a mobile phase of acetonitrile–1 g/L formic acid (75:25 by volume) at a flow rate of 0.5 mL/min.

Results: Extraction and separation of the three drugs and the internal standard were accomplished in 9 min. The overall extraction efficiency was >89% for all three compounds. The limits of detection were 1 µg/L for phenprocoumon and warfarin and 10 µg/L for acenocoumarol. Regression analysis of the calibration data revealed good correlation (r2 >=0.995) for all compounds. Within-run accuracies for quality-control samples were ± 1% to 7% of the target concentration, with CVs <9%.

Conclusions: The proposed method enables the unambiguous identification and quantification of phenprocoumon, warfarin, and acenocoumarol in both clinical and forensic specimens. This method combines a new, rapid solid-phase extraction procedure with an extremely fast chromatographic analysis, which is especially advantageous for clinical laboratories.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.